Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results forSHP
+29.42 (0.72%)
Jul 21 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,066.50 - 4,181.42
52 week 4,025.00 - 5,377.00
Open 4,108.50
Vol / Avg. 1.89M/2.26M
Mkt cap 37,452.76M*
P/E 86.08
Div/yield 20.64*
EPS 0.48*
Shares 907.99M
Beta     -
Inst. own     -
Aug 3, 2017
Q2 2017 Shire PLC Earnings Call - 2:00pm BST - Add to calendar
Aug 3, 2017
Q2 2017 Shire PLC Earnings Release - 12:00pm BST - Add to calendar
Jun 8, 2017
Shire PLC at Jefferies Healthcare Conference - Webcast
May 18, 2017
Shire PLC Conference Call to Discuss its Positive Topline Phase 3 Results for Lanadelumab in Patients With Hereditary Angioedema
May 4, 2017
Shire PLC at Deutsche Bank Health Care Conference - Webcast
May 2, 2017
Q1 2017 Shire PLC Earnings Call - Webcast
May 2, 2017
Q1 2017 Shire PLC Earnings Release
Apr 25, 2017
Shire PLC Annual Shareholders Meeting

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 9.95% 5.37%
Operating margin 13.92% 8.45%
EBITD margin - 30.21%
Return on average assets 2.14% 1.46%
Return on average equity 4.85% 3.11%
Employees 23,906 -
CDP Score - B


Hampshire Intl Business Park, Chineham
United Kingdom - Map
+44-1256-894000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 59
Jeffrey Poulton Chief Financial Officer, Executive Director
Age: 49
William Mordan General Counsel, Company Secretary
Age: 47
Perry Sternberg Head - U.S. Commercial
Age: 48
Kim Stratton Head - International Commercial
Age: 54
Philip J. Vickers Head - Research and Development
Age: 56
Matthew Walker Head - Technical Operations
Age: 53
Susan Saltzbart Kilsby Independent Non-Executive Chairman of the Board
Age: 58
Olivier Bohuon Non-Executive Director
Age: 58
Ian T. Clark Non-Executive Director
Age: 56